C50.019 ICD-10-CM Code: Malignant neoplasm of nipple and areola, unspecified female breast
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of breast (C50)
C50.019
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceMalignant neoplasm of nipple and areola, unspecified female breast
Breast cancer that starts in the nipple or areola on a female breast, but the specific side (left or right) is not documented.
Buddy Insight
Malignant neoplasm of the nipple and areola, unspecified female breast represents invasive breast cancer requiring staging, treatment planning, and ongoing surveillance.
CMS-HCC V28
00
RAF 0
CMS-HCC V24
MappedHCC 12
RAF 0.150
ACA/HHS
00
RAF 0
ESRD/PACE
MappedHCC 12
RAF 0.0
RXHCC
MappedHCC 22
RAF 0.0
Code Trumping
Basket needed
Code Book Path
Inclusion Terms
OfficialICD-10-CM does not list inclusion terms for C50.019 in this effective period.
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C50.019 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C50.019 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for C50.019 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C50.019 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C50.019 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C50.019 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.
Is C50.019 an HCC code?
Yes. C50.019 maps to Breast, Prostate, and Other Cancers and Tumors under the V24 model but is not retained in V28.
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C50.019
For C50.019to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C50.019 during that encounter, not just copy-forwarded from a problem list.
What This Code Means
C50.019 is the ICD-10-CM diagnosis code for malignant neoplasm of nipple and areola, unspecified female breast. Breast cancer that starts in the nipple or areola on a female breast, but the specific side (left or right) is not documented. C50.019 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of breast (c50).
Under the older CMS-HCC V24 model, C50.019 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Use this code only when laterality cannot be determined from the medical record. Because C50.019 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C50.019 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
Clinical Significance
Malignant neoplasm of the nipple and areola, unspecified female breast represents invasive breast cancer requiring staging, treatment planning, and ongoing surveillance. Breast cancer is risk-adjusted because it demands significant healthcare resources including surgery, radiation, chemotherapy, hormonal therapy, and long-term monitoring. The unspecified laterality indicates documentation does not identify the affected side, which should trigger a provider query.
Documentation Requirements
- ✓Pathologic confirmation of malignancy — distinguish Paget disease of nipple from invasive carcinoma with nipple involvement
- ✓Laterality must be queried if not documented — right or left breast
- ✓Gender documented as female to support gender-specific code selection
- ✓Quadrant or subsite location: nipple and areola
- ✓Tumor size (T stage) and grade
- ✓Lymph node status (N stage) — axillary, sentinel node biopsy results
- ✓Estrogen receptor, progesterone receptor, and HER2 status
- ✓Stage grouping (I-IV)
- ✓Current treatment status (active treatment, hormonal therapy, surveillance)
Commonly Confused Codes
- •C50.011 — Right female breast nipple/areola; preferred when right side documented
- •C50.012 — Left female breast nipple/areola; preferred when left side documented
- •C50.029 — Same laterality but male breast; verify patient gender
- •C50.111-C50.119 — Central portion of female breast; central portion is distinct from nipple/areola
- •D05.x — Carcinoma in situ of breast; must distinguish invasive from in situ disease